Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702271 · ClinicalTrials.gov registry record · NA
Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 458
- Enrollment target
NCT02702271: Completed NA study, sponsored by Boston Scientific Corporation.
NCT02702271 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 458 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02702271, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 458 participants
- Enrollment target
Study Summary
The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects with non-valvular atrial fibrillation who are eligible for long-term anti-coagulation therapy to reduce the risk of stroke but who have a rationale to seek a non-pharmacologic alternative.
Primary Outcome
The occurrence of one of the following events : all-cause death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair. Percutaneous catheter drainage of pericardial effusions, snaring of an embolized device, thrombin injection to treat femoral pseudoaneurysm and nonsurgical treatments of access site complications are captured
Interventions
- DEVICE WATCHMAN FLX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2021-03-12 |
| Phase | NA |
What the finished NCT02702271 record still lists
NCT02702271 is an interventional study that assigns participants to a tested intervention. The registered 458 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which WATCHMAN FLX is the first listed.
NCT02702271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02702271 about?
NCT02702271 is a clinical study titled "Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology". The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects with non-valvular atrial fibrillation who are eligible for long-term anti-coagulation therapy to reduce the risk of ...
What is the current status of trial NCT02702271?
This trial is currently completed. It is a NA study. The enrollment target is 458 participants. The study started on 2018-05-07. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT02702271?
The interventions under investigation include: WATCHMAN FLX (DEVICE).
Who is sponsoring clinical trial NCT02702271?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02702271's enrollment target sits among peer trials
458 224th of 2000 higher than 1,777 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05856942 · 458 participants · NA
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
- NCT06201676 · 458 participants · Phase 4
Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI